[Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders]
- PMID:23012855
[Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders]
Abstract
It is important to note that risperidone solution, intranasal administration of oxytocin, and dietary supplementation with large doses of arachidonic acid added to docosahexaenoic acid (DHA) have been reported to improve impaired social interaction. In addition, atypical antipsychotics aripiprazole and SSRI fluvoxamine were useful in treating some aspects of social relatedness or the core deficits of communication and socialization. The evaluation of treatments for ASD should be directed at neurobiological targets known to be important in the brain's response to abnormal developmental trajectories or toward enhancing plasticity during the highly sensitive period in gene-environment interaction (epigenetic mechanism). Recent epidemiological studies have indicated that at least one in every 100 people has some form of ASD. Environmental chemicals can affect the development of the brain. Further studies will be required to address the effect of environmental chemicals.
Similar articles
- Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder.Huang SC, Tsai SJ, Yang HJ.Huang SC, et al.Chang Gung Med J. 2010 Mar-Apr;33(2):211-5.Chang Gung Med J. 2010.PMID:20438675
- Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial.Yui K, Koshiba M, Nakamura S, Kobayashi Y.Yui K, et al.J Clin Psychopharmacol. 2012 Apr;32(2):200-6. doi: 10.1097/JCP.0b013e3182485791.J Clin Psychopharmacol. 2012.PMID:22370992Clinical Trial.
- New directions in the treatment of autism spectrum disorders from animal model research.Chadman KK, Guariglia SR, Yoo JH.Chadman KK, et al.Expert Opin Drug Discov. 2012 May;7(5):407-16. doi: 10.1517/17460441.2012.678828. Epub 2012 Apr 12.Expert Opin Drug Discov. 2012.PMID:22494457Review.
- Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone.Ishitobi M, Hiratani M, Kosaka H, Takahashi T, Mizuno T, Asano M, Murata T, Tomoda A, Wada Y.Ishitobi M, et al.Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):128-31. doi: 10.1016/j.pnpbp.2011.12.015. Epub 2012 Jan 8.Prog Neuropsychopharmacol Biol Psychiatry. 2012.PMID:22245026
- Role of risperidone in children with autism spectrum disorder.Chavez B, Chavez-Brown M, Rey JA.Chavez B, et al.Ann Pharmacother. 2006 May;40(5):909-16. doi: 10.1345/aph.1G389. Epub 2006 Mar 7.Ann Pharmacother. 2006.PMID:16684811Review.
Cited by
- Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D.Iffland M, et al.Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.Cochrane Database Syst Rev. 2023.PMID:37811711Free PMC article.Review.
- Aripiprazole for treating irritability in children & adolescents with autism: A systematic review.Ghanizadeh A, Tordjman S, Jaafari N.Ghanizadeh A, et al.Indian J Med Res. 2015 Sep;142(3):269-75. doi: 10.4103/0971-5916.166584.Indian J Med Res. 2015.PMID:26458342Free PMC article.Review.
- Docosahexaenoic and Eicosapentaenoic Intervention Modifies Plasma and Erythrocyte Omega-3 Fatty Acid Profiles But Not the Clinical Course of Children With Autism Spectrum Disorder: A Randomized Control Trial.de la Torre-Aguilar MJ, Gomez-Fernandez A, Flores-Rojas K, Martin-Borreguero P, Mesa MD, Perez-Navero JL, Olivares M, Gil A, Gil-Campos M.de la Torre-Aguilar MJ, et al.Front Nutr. 2022 Mar 29;9:790250. doi: 10.3389/fnut.2022.790250. eCollection 2022.Front Nutr. 2022.PMID:35425788Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Medical